## 1 Safety and superior immunogenicity of heterologous boosting with an

# 2 **RBD-based SARS-CoV-2 mRNA vaccine in Chinese adults**

- 3 Xiaoqiang Liu<sup>\*1</sup>, Yuhua Li<sup>\*2</sup>, Zhongfang Wang<sup>\*3</sup>, Shouchun Cao<sup>\*2</sup>, Weijin Huang<sup>\*2</sup>,
- 4 Lin Yuan<sup>\*4</sup>, Yi-Jiao Huang<sup>5</sup>, Yan Zheng<sup>1</sup>, Jingjing Chen<sup>4</sup>, Bo Ying<sup>6</sup>, Zuoyun Xiang<sup>4</sup>,
- 5 Jin Shi<sup>4</sup>, Jincun Zhao<sup>#3</sup>, Zhen Huang<sup>#4</sup>, & Cheng-Feng Qin<sup>#5,7</sup>
- 6 1. Yunnan Province Centre for Disease Control and Prevention, Kunming, Yunnan, 7 China. 2. National Institutes for Food and Drug Control, Beijing, China. 8 3. Respiratory Medicine, Guangzhou Institute of Respiratory Health, Guangzhou, 9 Guangdong, China. 10 4. Walvax Biotechnology Co., Ltd., Kunming, Yunnan China. 11 5. State Key Laboratory of Pathogen and Biosecurity, Beijing Institute of Microbiology 12 and Epidemiology, Academy of Military Medical Sciences, Beijing, China. 13 14 6. Suzhou Abogen Biosciences Co., Ltd., Suzhou, Jiangsu, China. 7. Research Unit of Discovery and Tracing of Natural Focus Diseases, Chinese 15 Academy of Medical Sciences, Beijing, China 16 17
- \*These authors contributed equally: Xiaoqiang Liu, Yuhua Li, Zhongfang Wang,Shouchun Cao, Weijin Huang, Lin Yuan.
- <sup>#</sup>Correspondence to Cheng-Feng Qin (qincf@bmi.ac.cn), Zhen Huang (hz@walvax.com),
- 21 or Jincun Zhao (zhaojincun@gird.cn)

### 23 Abstract

Homologous and heterologous booster with COVID-19 mRNA vaccines represent the 24 most effective strategy to prevent the ongoing Omicron pandemic. The additional 25 26 protection from these prototype SARS-CoV-2 S-targeting vaccine was attributed to the 27 increased RBD-specific memory B cells with expanded potency and breadth. Herein, we show the safety and immunogenicity of heterologous boosting with the RBD-28 targeting mRNA vaccine AWcorna (also term ARCoV) in Chinese adults who have 29 received two doses inactivated vaccine. The superiority over inactivated vaccine in 30 neutralization antibodies, as well as the safety profile, support the use of AWcorna as 31 32 heterologous booster in China.

### 33 Introduction

To May 2022, the COVID-19 pandemic has claimed more than 6.28 million lives, with 34 more than 524 million confirmed cases worldwide. The recent emergence of highly 35 transmissible Omicron variant of severe acute respiratory syndrome coronavirus 2 36 37 (SARS-CoV-2) has triggered another major surge in both confirmed cases and deaths<sup>1</sup>. Ten COVID-19 vaccines have been approved by the World Health Organization (WHO) 38 for emergency use, including the two mRNA vaccines, BNT162b2 and mRNA-1273, 39 and two Chinese inactivated vaccines, CoronaVac and BBIBP-CorV. However, the 40 41 rapid waning of vaccine-induced virus-neutralizing antibody titers and the continuous emergence of variants of concern (VOCs), including Alpha, Beta, Delta and Omicron, 42 have created unprecedented challenges in the eradication of COVID-19 pandemic<sup>2-4</sup>. 43

Especially, the heavily mutated Omicron variant has been well characterized to escape from most therapeutic monoclonal antibodies, as well as sera from convalescent patients or fully vaccinated individuals<sup>5,6</sup>. Recent data has indicated that neutralizing antibody against Omicron was absent or undetectable in most Chinese populations who received two-dose inactivated vaccines<sup>7</sup>. Interestingly, preliminary data have suggested that a booster dose with mRNA vaccine BNT162b2 showed significant superiority over

homologous booster in titers and protection against Omicron<sup>7-9</sup>. However, the two 50 commercial mRNA vaccines, encoding the full S protein of SARS-CoV-2, are not 51 available in mainland China. The "made-in-China" mRNA vaccine candidate AWcorna 52 (originally termed ARCoV), which encodes the Receptor Binding domain (RBD) of 53 SARS-CoV-2 S protein, is being tested in the final stage of multiple-center phase III 54 55 trials (https://clinicaltrials.gov/ct2/show/NCT04847102). It is of highly priority and 56 urgency to provide evidence to support a better boosting strategy in mainland China for 57 decision maker.

#### 58 **Results**

59 Herein, we reported the safety and immunogenicity of a third dose of heterologous boosting with AWcorna in Chinese adults who have received two-dose inactivated 60 vaccines. The randomized clinical trial (ChiCTR2100053701) enrolled 300 adults 61 (ages≥18 years). All eligible subjects received 2-dose priming vaccination with the 62 inactivated vaccine, CoronaVac or BBIBP-CorV. At about 6-month post-priming, all 63 subjects were randomly assigned to either the AWcorna (n=200; heterologous) or 64 CoronaVac (n=100; homologous) booster group (Supplementary information, Fig. 65 S1a). In the AWcorna group, the median age was 43.0 years (Interquartile rate, IOR: 66 67 36.5-49.0), and the CoronaVac group was 40.0 years (IQR: 34.0-48.5) (P=0.5165) (Supplementary information, Table S1). There were 116 (58%) and 55 (55%) male 68 participants in the AWcorna and CoronaVac groups, respectively (P=0.6208). 69 Meanwhile, no significant differences were observed in the Body Mass Index (BMI), 70 71 vital signs, and comorbid condition between the two groups at the baseline (All P>0.05). 72 All subjects completed the enrollment vaccination and three blood examinations consecutively at pre-booster or 0 days, 14±2 days, and 28±2 days post-booster 73 vaccination. Subsequently, the neutralization and IgG antibody titers against wild-type 74 75 (WT) SARS-CoV-2 and VOCs were assessed at pre-booster, 14- and 28-day postbooster by the standard cytopathic effect (CPE) based assay and ELISA, respectively 76

(Supplementary information, Methods). The WHO standard IgG antibody (NIBSC
code 20/136) was used as a reference sample for all serological assays.

As expected, the live virus neutralization titers against WT SARS-CoV-2 were below 79 80 the detection limit before boosting in all participants from both groups (Fig. 1a). 81 Remarkably, AWcorna booster induced a 66.59-fold increase against WT SARS-CoV-2, and the geometric mean titers (GMTs) reached 293.9 and 242.4 at 14 and 28 days 82 post booster, respectively (WHO Reference cut-off 1:139), while the GMTs in 83 CoronaVac booster groups was only 89.1 and 64.3, respectively (Fig. 1a and 84 supplementary information, Table S2). Similarly, the neutralization antibody titers 85 against the Delta variant also increased significantly after the third dose booster either 86 87 with AWcorna and CoronaVac, while the GMTs in Awcorna groups were 5.1- and 6.5fold higher than that in CoronaVac group at 14 and 28 days post booster (Fig. 1b and 88 89 supplementary information, **Table S2**). In addition, the increasing trends are similar in both 18-59 and  $\geq 60$  years old participants (Supplementary information, Fig. S2a,b). 90

Despite the neutralization antibody titers against the Omicron variant showed 91 92 significant reduction in comparison with that against the WT virus in both groups, the 93 GMTs against Omicron maintained 28.1 at 28-day after AWcorna booster, while the 94 GMT in the CoronaVac booster group was only 6.4 (Fig. 2a and supplementary 95 information, **Table S2**). Most importantly, 83.75% of participants in the AWcorna 96 booster group achieved the 1:8 threshold of neutralization antibody titers against the Omicron relative to that of only 35% of participants in the CoronaVac booster group 97 98 (**Fig. 2b**; 95% Confidence Interval, CI: 30.82-63.84; *P*<0.0001).

99 Moreover, the RBD-specific IgG antibodies titers also showed a sharp increasement in 100 both booster groups, and the GMT in AWcorna booster group was 6.8- and 7.1- fold 101 higher than that in the CoronaVac booster group at both 14-day and 28-day time points, 102 respectively (all *P*<0.0001) (**Fig. 3a** and supplementary information, **Table S3**). Taken 103 together, these results demonstrate that heterologous boosting with AWcorna induces

higher neutralization and IgG antibodies against WT, Delta and Omicron variants thanhomologous booster.

Additionally, we observed the safety profile of the booster dose of AWcorna. Solicited 106 107 local and systemic adverse events (AEs) were recorded within 30 mins and in a window 108 of 0-14 days, and unsolicited AEs were documented within 0-28 days post-booster vaccination (Supplementary information, Table S4). For both vaccines, pain at the 109 injection site is the most reported local AE (incidence rate, IR:17% in AWcorna vs. 2% 110 in CoronaVac; P<0.0001), mostly at the Grade 1 level (Fig. 4a). Fever was the most 111 common systemic AE (IR: 33.5%), followed by headache (IR: 26.0%) and muscle 112 aches (IR: 7.5%) in AWcorna group (Fig. 4b). A total of 8 subjects reported grade 3 113 fever (IR:4%) among the 200 participants in AWcorna group. For the CoronaVac group, 114 headache represented as the most frequent systemic AE (IR: 7.0%), followed by fever 115 116 (IR: 4.0%). No serious adverse events (SAE) were reported in both groups.

#### 117 Discussion

Collectively, our present study clearly demonstrated that a 3<sup>rd</sup> dose of heterologous 118 boosting with AWcorna was safe and potential protective against the circulating Delta 119 and Omicron variants. Compared with phase 1 trial, the total IRs of local and systemic 120 AEs for AWcorna booster showed significant improvement<sup>10</sup>, especially the IR of grade 121 122 3 fever reduced to 4% (Supplementary information, Table S4), which was comparable to the other two approved mRNA vaccines<sup>11</sup>. The phase 1 trial of AWcorna only 123 included 20 adults aged 18-59 (15 µg group), while our present cohort enrolled 200 124 participants, including 10 subjects aged over 60. The expansion of sample size and 125 improvement in vaccine manufacturing technologies contributed to the improved safety 126 profile observed in our present study. The ongoing international phase 3 trials with 127 28,000 participants will provide more meaningful data about the safety profile of 128 AWcorna. 129

Previously, we have demonstrated that homologous boosting with AWcorna readily 130 induced high neutralization antibodies against WT and Omicron variant in mice<sup>12</sup>, our 131 132 present data in human further supported heterologous booster with this China-made mRNA vaccine AWcorna in Chinese populations. Many cities in China are under the 133 attack of Delta and Omicron variants, while few or no neuralization antibodies against 134 Omicron was detected in most Chinese populations<sup>7,13</sup>, a third dose of booster has been 135 recommended by the WHO and National Health Commission of China. Of all COVID-136 137 19 vaccines generated from different technology platform, mRNA vaccine represents as the most reasonable choice as either homologous or heterologous booster. The 138 neutralization titers against Delta and Omicron variants in AWcorna booster group were 139 6.5-fold and 4.4-fold higher than that in CoronaVac booster group, respectively (Fig. 140 **1b**, **c**), and the AWcorna booster induced the seroconversion of Omicron neutralization 141 in over 83% individuals (Fig. 1d). A third dose of S-targeting mRNA vaccine was 142 evidenced to increase the number of RBD-specific memory B cells with expanded 143 potency and breadth, thus contributing to the additional protection against VOCs 144 including Omicron<sup>14,15</sup>, highlighting the rationale of RBD-targeting mRNA vaccine as 145 booster. Given that more and more Chinese population have received three-dose 146 inactivated vaccines, additional clinical trials are being conducted to assay the benefits 147 148 of heterologous boosting with AWcorna.

Finally, despite the vaccine effectiveness of AWcorna booster in preventing infection by SARS-CoV-2 and other VOCs remains to be determined, the induction of potent neutralization antibodies against WT and VOCs, as well as the affordable safety profile, support the emergency use of AWcorna as heterologous booster in China. A more potent mRNA vaccine and improved booster strategy should be warranted to meet the urgent and huge need to stop the ongoing Omicron outbreaks in China and COVID-19 pandemic worldwide.

#### 156 METHODS AND MATERIALS

157 **Study design** 

We conducted a randomized clinical trial involving 300 adults (≥18 years of age) who
were tested negative by RT-PCR screening for COVID-19 at the time of participation
to elucidate the immunogenicity and safety of an mRNA-based vaccine (AWcorna) as
a booster compared to that of homologous booster using an inactivated viral vaccine
(CoronaVac).

### 163 Ethics statement

The trial was reviewed and approved by the Research Ethics Committee of the Center for Disease Control and Prevention of Yunnan province. The study protocol and related materials were approved by the independent Ethics Committees as well, and this trial was conducted in accordance with the Declaration of Helsinki and Good Clinical Practice with the register number of ChiCTR2100053701 (NO. 2021-15). Written informed consents were obtained from each participant before the screening.

#### 170 **Participants**

Eligible participants met all inclusion criteria and did not trigger any exclusion criteria. 171 Those aged 18 years and above, received full 2-dose inactivated viral priming around 172 173 6 months ago. Of the 300 participants, 175 received 2-dose CoronaVac, 14 received 2dose BBIBP CorV, and 111 received one-dose CoronaVac and 1-dose BBIBP CorV. 174 Participants with a previous clinical or virologic COVID-19 diagnosis or SARS-CoV-175 2 infection or women with positive urine pregnancy test results were excluded from this 176 study. Participants with a medical history of convulsion, serious acute hypersensitive 177 reaction to vaccines, acute febrile diseases or infectious diseases, congenital or acquired 178 angioedema, asplenia or functional asplenia, thrombocytopenia or other coagulation 179 180 disorders, anti-allergy therapy, or blood products within 3 months were also excluded.

#### 181 **Randomization**

182 Each participant was assigned a unique subject ID by authorized assigners successively183 according to a Prespecified allocation kit, which was generated by an independent

randomization statistician from Beijing Key Tech Statistical Consulting Co., Ltd. via 184 SAS software (SAS® Institute, Cary, North Carolina, USA) with the ratio of 2:1 to the 185 AWcorna and CoronaVac groups. Since the different appearances of the two kinds of 186 vaccines, inoculators could not keep in blind when vaccines had been used. And hence, 187 staff who were assigned to inoculate would not be involved in any other research jobs, 188 especially for subjects' safety follow-up procedures. Participants would be masked 189 when receiving the jab by a special curtain in the injection room to avoid the 190 191 identification of he or she, and disclosure of the allocated group. Other investigators, laboratory staff, and outcome assessors were kept blinded also. 192

#### 193 Interventions

The AWcorna vaccine (15  $\mu$ g/dose) (batch number RR202109006) is manufactured by Yuxi Walvax Biotechnology Co. Ltd. (an affiliate of Walvax Biotechnology Co., Ltd.), and supplied in pre-filled 0.5 ml syringes. The CoronaVac (Sinovac) vaccine, is an inactivated whole-virion vaccine with aluminum hydroxide as the adjuvant. Each dose of CoronaVac contains 3  $\mu$ g SARS CoV-2 virion in a 0.5 ml aqueous suspension for injection with 0.45 mg/ml aluminum.

#### 200 Assessments

After injection, subjects received an in-site 30-minutes safety observation conducted 201 by research staff to confirm if any immediate reactions occurred. Any adverse events 202 203 (AEs) discovered or any relevant concomitant medications declared within 28 days after vaccination were recorded by subjects with the help of the daily cards and 204 205 connections cards which were prepared and managed by the study team. For each subject, serious adverse events (SAEs), adverse events of interest (AESI), and 206 pregnancy were collected from the enrollment till 12 months after his/her booster dose. 207 Up to 6 ml of blood sample was collected from each participant at baseline pre-booster 208 vaccination and on day 14 and day 28 after receiving the booster dose. 209

### 210 Endpoints

The primary endpoints for safety were: 1) The incidence rates of adverse reactions/adverse events within 30 minutes, during Day 0-14 and Day 0-28 after vaccination; and 2) The incidence rates of adverse reactions/adverse events with a severity of grade 3 and above within 30 minutes and during Day 0-14 and Day 0-28 after vaccination. The primary immunogenicity endpoint was the titers of neutralizing antibody against wild type SARS-CoV-2 as measured by live virus neutralization assay 14 days post booster.

### 218 Laboratory assays

The neutralizing antibodies in sera against the wild-type strain (GenBank: MT123291), 219 220 Delta variant (IQTC-IM2175251), and Omicron variant (IQTC-Y216017) (Guangzhou Customs Technology Center, Guangzhou, China) were determined by using a 221 cytopathic effect (CPE)-based microneutralization assay. Two-fold serial dilutions 222 (starting from 1:4) of heat-inactivated sera were tested in duplicate wells for the 223 224 presence of neutralizing antibodies in the monolayer of Vero E6 cells. 100 TCID<sub>50</sub> of virus in 50 µl/well was incubated with 50 µl of serum in 96-well plates for 2 h. Vero 225 E6 cells were trypsinized and resuspended in Dulbecco's Modified Eagle Medium 226 (DMEM) containing 4% of fetal bovine serum and 1% of pen/strep at a concentration 227 of  $1.2 \times 10^5$  cells/ml and 100 µl of cells suspension were then added into the 96-well 228 plates, followed by incubation at 37 °C, 5% CO<sub>2</sub> for 4 days. The neutralization was 229 determined by the appearance of CPE in images captured with Celigo Image Cytometer 230 on day 4 post-infection. The neutralizing antibody titer was defined as the reciprocal of 231 232 the highest sample dilution that protected at least 50% of cells from CPE.

RBD-specific ELISA antibody responses were measured using an indirect ELISA assay
with a cutoff titer of 1:10. The commercial Anti-SARS-CoV-2 RBD IgG ELISA kit
was used for detection. Measurement was performed using a Multiskan GO reader

(Thermo Fisher) to detect optical density at 450 and 630 nm using SkanIt Software forMicroplate Readers (version 4.1.0.43).

The WHO international standard for anti-SARS-CoV-2 IgG (NIBSC code 20/136) was 238 239 used as a reference with the serum samples measured in this study for calibration of the 240 serological assays. The WHO reference (NIBSC code: 20/136) is equivalent to a live viral neutralizing antibody titer of 1:139 against wild-type SARS-CoV-2 and a titer of 241 1:213 against the Delta variant B.1.617.2, while the WHO reference (1,000 BAU/ml in 242 serum) is equivalent to an RBD-specific IgG ELISA antibody titer of 1:5,490. Live 243 viral neutralizing antibodies against wild-type strain and the Delta variant and levels of 244 RBD-binding IgG isotypes in serum were measured on days 0, 14, and 28 after the 245 booster. Live viral neutralizing antibodies against the Omicron variant BA.1.1 were 246 detected only on day 28 after the booster in a subgroup randomly selected from both 247 248 groups.

#### 249 Sample size

250 The sample size was determined based on the hypothesis that the booster vaccination of mRNA vaccine following the two-dose inactivated vaccine regimen be non-inferior 251 to that of the booster of inactivated vaccine in neutralizing antibody. It was assumed 252 that the pooled standard deviation of  $\log_{10}$ -transformed neutralizing data was 0.5 and 253 254 equal GMT in both the mRNA vaccine group and CoronaVac group. 200 participants in the mRNA group and 100 participants in the CoronaVac group could have at least 255 80% power to observe that the lower limit of the 95% confidence interval of GMT ratio 256 between the two groups was greater than the non-inferiority margin (2/3), with the one-257 258 sided significance level of 2.5%.

### 259 Statistical analysis

The geometric mean titer (GMT) and 95% confidence interval (CI) were used to describe neutralizing results in the mRNA vaccine group and CoronaVac group after booster vaccination, and the GMT ratio between the two groups and 95% CI were estimated. The non-inferiority result would be concluded if the lower bound of 95% CI was larger than 2/3. When the non-inferiority conclusion was concluded, the superiority would be considered sequentially if the lower bound was larger than 1. The seroconversion rate and Clopper-Pearson 95% CI after booster vaccination were estimated as well, and the difference between the two groups was calculated using the Miettinen-Nurminen method.

269 We assessed the number and proportion of participants with adverse reactions 0-28 days after the booster dose. For fever, besides the NMPA standard, we also derived the oral 270 271 temperature by adding  $0.2^{\circ}$  to the collected auxiliary temperature, and then re-graded the adverse reaction based on the FDA standard to provide more comparable results 272 with marketed vaccines. We used the  $\chi^2$  test or Fisher's exact test to analyze categorical 273 274 data, the t-test to analyze the log-transformed antibody titers, and the Wilcoxon ranksum test for data not following a normal distribution. The correlation between 275 concentrations of log-transformed neutralizing antibody and binding antibody levels 276 was analyzed using Pearson's correlation. The primary analysis was performed based 277 on the per-protocol population. Statistical analyses were performed using SAS (version 278 279 9.4).

#### 280 ACKNOWLEDGMENTS

We thank all the participants in this trial and all staff in the research sites at Lancang 281 CDC and Yunnan CDC. The authors acknowledge members from the Guangzhou 282 283 Institute of Respiratory Health, Guangzhou Customs Technology Center, the Vazyme 284 Medical Technology, the Beijing Key Tech Statistical Consulting, and the Beijing Stem Technology for technical support and collaboration. We sincerely thank Prof. Xuanyi 285 Wang and Prof. Haifeng Li for critical reading and insightful suggestion for this 286 manuscript. This work was supported in part by grant from the National Key Research 287 and Development Program of China (2021YFC2302400) and the National Science 288 Foundation of China (82151222). C.-F.Q. was supported by the National Science Fund 289

for Distinguished Young Scholars (81925025), the Innovative Research Group
(81621005) from the National Science Foundation of China and the Innovation Fund
for Medical Sciences (2019-I2M-5-049) from the Chinese Academy of Medical
Science.

### 294 AUTHOR CONTRIBUTIONS

J.Z., Z.H. and C.-F.Q. conceived and supervised the project. X.L., J.Z., Z.W. and L.Y.
designed and coordinated the experiments. J.Z. and Z.W. performed the laboratory
assays. Y.L., W.H., and S.C. completed the quality assurance of this product and
provided essential guidance on laboratory assays. J.S. and B.Y. provided technical
expertise on mRNA vaccine production. Y.Z. and J.C. analyzed the data. L.Y., J.C., Y.J.H., Z.X. and C.-F.Q. drafted the manuscript. All authors revised and approved the
final version.

#### **302 COMPETING INTERESTS**

This trial was sponsored by the Walvax Biotechnology. AWcorna was co-developed by
AMMS, Abogen, and Walvax. C.-F. Q. and B.Y. are co-inventor of AWcorna. Z.H.,
L.Y., J.C., Z.X. and J.S. are employees of Walvax. B. Y. is the founder of Abogen. The
other authors declare no conflicts of interest.

### 307 **REFERENCES**

3081Cao, Y. et al. Omicron escapes the majority of existing SARS-CoV-2 neutralizing309antibodies. Nature 602, 657-663, doi:10.1038/s41586-021-04385-3 (2022).

- Levin, E. G. *et al.* Waning Immune Humoral Response to BNT162b2 Covid-19 Vaccine
  over 6 Months. *The New England journal of medicine* 385, e84,
  doi:10.1056/NEJMoa2114583 (2021).
- 313 3 Cao, Y. *et al.* Humoral immunogenicity and reactogenicity of CoronaVac or ZF2001
  314 booster after two doses of inactivated vaccine. *Cell Res* 32, 107-109,
  315 doi:10.1038/s41422-021-00596-5 (2022).
- Ai, J. *et al.* Recombinant protein subunit vaccine booster following two-dose
  inactivated vaccines dramatically enhanced anti-RBD responses and neutralizing titers
  against SARS-CoV-2 and Variants of Concern. *Cell Res* 32, 103-106,
  doi:10.1038/s41422-021-00590-x (2022).

320	5	Planas, D. et al. Considerable escape of SARS-CoV-2 Omicron to antibody
321		neutralization. Nature 602, 671-675, doi:10.1038/s41586-021-04389-z (2022).
322	6	Wang, K. et al. Memory B cell repertoire from triple vaccinees against diverse SARS-
323		CoV-2 variants. <i>Nature</i> <b>603</b> , 919-925, doi:10.1038/s41586-022-04466-x (2022).
324	7	Cheng, S. M. S. et al. Neutralizing antibodies against the SARS-CoV-2 Omicron variant
325		BA.1 following homologous and heterologous CoronaVac or BNT162b2 vaccination.
326		Nat Med <b>28</b> , 486-489, doi:10.1038/s41591-022-01704-7 (2022).
327	8	Mok, C. K. P. et al. Comparison of the immunogenicity of BNT162b2 and CoronaVac
328		COVID-19 vaccines in Hong Kong. Respirology 27, 301-310, doi:10.1111/resp.14191
329		(2022).
330	9	Jara, A. et al. Effectiveness of homologous and heterologous booster doses for an
331		inactivated SARS-CoV-2 vaccine: a large-scale prospective cohort study. Lancet Glob
332		<i>Health,</i> doi:10.1016/S2214-109X(22)00112-7 (2022).
333	10	Chen, G. L. et al. Safety and immunogenicity of the SARS-CoV-2 ARCoV mRNA vaccine
334		in Chinese adults: a randomised, double-blind, placebo-controlled, phase 1 trial. The
335		Lancet. Microbe <b>3</b> , e193-e202, doi:10.1016/s2666-5247(21)00280-9 (2022).
336	11	Munro, A. P. S. et al. Safety and immunogenicity of seven COVID-19 vaccines as a third
337		dose (booster) following two doses of ChAdOx1 nCov-19 or BNT162b2 in the UK (COV-
338		BOOST): a blinded, multicentre, randomised, controlled, phase 2 trial. Lancet 398,
339		2258-2276, doi:10.1016/S0140-6736(21)02717-3 (2021).
340	12	Zhang, N. N. et al. Rapid development of an updated mRNA vaccine against the SARS-
341		CoV-2 Omicron variant. Cell Res, doi:10.1038/s41422-022-00626-w (2022).
342	13	Zhang, R. et al. A protein subunit vaccine booster following two doses of inactivated
343		SARS-CoV-2 vaccine provides high neutralisation of SARS-CoV-2 and its variants in
344		mice. Lancet Microbe <b>3</b> , e165-e166, doi:10.1016/S2666-5247(21)00331-1 (2022).
345	14	Muecksch, F. et al. Increased Memory B Cell Potency and Breadth After a SARS-CoV-2
346		mRNA Boost. <i>Nature,</i> doi:10.1038/s41586-022-04778-y (2022).
347	15	Goel, R. R. et al. Efficient recall of Omicron-reactive B cell memory after a third dose
348		of SARS-CoV-2 mRNA vaccine. <i>Cell</i> , doi:10.1016/j.cell.2022.04.009 (2022).
349		







Fig.1 GMT of neutralizing antibodies to live wild-type SARS-CoV-2 or Delta variant.

**Delta Variant** 

a Geometric mean titer (GMT) of neutralizing antibodies to live wild-type (WT) SARS-354 CoV-2. The WHO reference serum (1,000 IU/ml) was equivalent to a live viral 355 neutralizing antibody titer of 1:139 against WT. b GMT of neutralizing antibodies to 356 the Delta variant. The WHO reference was 1:213 against the Delta variant (the dash 357 line in red). Eligible participants primed with 2-does of inactivated vaccine were 358 randomly allocated to AWcorna group (n=200) and CoronaVac group (n=100) to 359 receive a booster dose respectively. GMT data are presented in box-and-whisker plots. 360 361 The figures above error bars indicate the percentage. P values were obtained from comparisons between the two treatment groups using t-tests for log-transformed 362 antibody or two-sided  $\chi^2$  tests for categorical data. 363



365

### 366 Fig.2 GMT of neutralizing antibodies to Omicron variant.

a GMT of neutralizing antibodies to the Omicron variant was measured in the subgroup 367 368 (120 participants with the first 120 subject numbers, 80 from AWcorna and 40 from 369 CoronaVac group). Sera were measured 28 days after booster only, thus no baseline 370 analysis was performed. b Seropositive rates (%) of neutralizing antibody to the Omicron variant. GMT data are presented in box-and-whisker plots. The figures above 371 372 error bars indicate the percentage. P values were obtained from comparisons between the two treatment groups using *t*-tests for log-transformed antibody or two-sided  $\chi^2$ 373 374 tests for categorical data.

376 a



377

### 378 Fig.3 GMT of anti-RBD IgG antibodies to WT SARS-CoV-2.

a GMTs of anti-RBD IgG antibodies to WT SARS-CoV-2. The WHO reference (1,000 binding antibody unit (BAU)/ml in serum) is equivalent to an RBD-specific IgG ELISA antibody titer of 1:5490. The cutoff value for the response was 1:8 for live virus neutralizing antibody and 1:10 for anti-RBD IgG. GMT data are presented in box-andwhisker plots. The figures above error bars indicate the percentage. *P* values were obtained from comparisons between the two treatment groups using *t*-tests for logtransformed antibody or two-sided  $\chi^2$  tests for categorical data.



b



387

388

### 389 Fig.4 Safety of Heterologous boosting with AWcorna in Chinese adults.

**a** The percentage of participants with local adverse events (AEs). **b** The percentage of

- participants with systemic AEs. These AEs were monitored in the 14 days window afterthe administration of the booster.
- 393
- 394
- 395



396

397

### 398 Fig. S1 Consolidated standards of reporting trials (CONSORT) flow diagram

a Between the trial screening and randomization, 29 volunteers were excluded. All of them
triggered the exclusion criteria. A total of 300 eligible subjects, who had received 2 doses of
inactivated vaccine about 6 months ago, were randomly assigned to either the AWcorna (n=200;
heterologous) or CoronaVac (n=100; homologous) booster group. All the randomized
participants received vaccines at their free will and received all the scheduled follow-ups.

404

405







а



407

### 408 Fig.S2 Cross neutralization against WT and Delta viruses in different age groups.

**a,b** GMT of neutralizing antibodies to wild-type SARS-CoV-2 and Delta variant for younger 409 adult population aged 18-59 (AWcorna=190, CoronaVac=90) (a) and elder population aged 60 410 411 and above (AWcorna=10, CoronaVac=6) (b). GMT data are presented in box-and-whisker 412 plots. The whiskers indicate the range, the top and bottom of the boxes indicate the interquartile range, and the horizontal line within each box indicates the median. Figures with the x suffix 413 414 indicate the GMT ratio between groups or GMT increase fold raised from pre- to post-booster level. P values were obtained from comparisons between the two treatment groups using t-tests 415 416 for log-transformed antibody.

### 418 Table S1. Baseline characteristics of the trial participants, who had received two doses of

### 419 priming inactivated vaccine.\*

	AWcorna	CoronaVac	D Value	
	(N=200)	(N=100)	<i>P</i> -Value	
Age(Median, IQR)	43.0 (36.5,49.0)	40.0 (34.0,48.5)	0.5165	
Sex, male(%)	116 (58.00)	55 (55.00)	0.6208	
	23.56	23.22	0.2000	
BMI(min-max)	(15.58-34.53)	(18.31-33.31)	0.3998	
Ethnicity‡				
Lahu, n(%)	179 (89.50)	88 (88.00)	0.5418	
Wa, n(%)	1 (0.50)	0 (0.00)		
Hani, n(%)	10 (5.00)	3 (3.00)		
Yi, n(%)	2 (1.00)	1 (1.00)		
Dai, n(%)	0 (0.00)	0 (0.00)		
Other, n(%)	8 (4.00)	8 (8.00)		
RT-PCR, negative(%)	200(100)	100(100)	1.0000	
Vital Signs				
Systolic Pressure	118(81-141)	118(85-140)	0.9615	
Diastolic Pressure	73(48-89)	74(56-90)	0.3679	
Pulse	79(56-114)	81(53-110)	0.2182	
Comorbidities				
Any (%)	9	9	1.0000	
Gastrointestinal disorders (%)	3.5	2	0.7227	
Vascular disorders (%)	1	2	0.6030	
Respiratory, thoracic and mediastinal disorders (%)	1.5	0	0.5533	
Infections and infestations (%)	1	1	1.0000	
Musculoskeletal and connective tissue disorders (%)	0.5	1	1.0000	
Nervous system disorders (%)	0.5	1	1.0000	
Blood and lymphatic system disorders (%)	1	0	0.5541	
Endocrine disorders (%)	0	1	0.3333	
Investigations (%)	0.5	0	1.0000	
Reproductive system and breast disorders (%)	0	1	0.3333	
SARS-CoV-2 specific antibody titers on day 0§				
Geometric Mean Titer of anti-RBD IgG (Mean, 95%CI)				
	134.7	140.8	0.7061	

	(118.3, 153.4)	(115.3, 172.0)	
Geometric Mean Titer of nAb against Wild-Type SARS-Co	oV-2 (Mean, 95%CI)		
	4.4(4.2, 4.7)	4.5(4.2, 4.9)	0.7831
Geometric Mean Titer of nAb against Delta Variant (Mean,	95%CI)		
	4.2(4.0, 4.4)	4.1(4.0, 4.3)	0.5951

\* The first trial visit occurred before the booster, and the second and third trial visit occurred 14- and 28-days after
administration of the booster. IQR denotes interquartile range.

422 † The body-mass index (BMI) is the weight in kilograms divided by the square of the height in meters.

423 ‡ Categories were reported by the participants. The categories shown are those used by the investigators to denote

- 424 ethnicity.
- 425 § In the two groups, blood was drawn on day 0, which was the day of the first trial visit. Day 0 was also the day of
- the booster in the two groups.

	AWcorna	CoronaVac	GMT/GMI Ratio (AWcorna /CoronaVac)	Statistics	P value
	N=200	N=100	or Diff. in % (AWcorna -CoronaVac)		
Wild-Type					
Pre-Booster					
GMT	4.4(4.2, 4.7)	4.5(4.2, 4.9)	NA	<i>t</i> =-0.275	0.7831
Seropositive <sup>*</sup> (%)	9.00(5.42, 13.85)	10.00(4.90, 17.62)	NA	χ <sup>2</sup> =0.079	0.7790
D14					
GMT	293.9(260.4, 331.7)	89.1(73.7, 107.8)	3.3(2.7, 4.1)	NA	< 0.0001
GMI	66.2(58.3, 75.1)	19.8(16.3, 24.0)	3.3(2.7, 4.2)	NA	< 0.0001
Seroconversion*(%)	99.00(96.43, 99.88)	98.00(92.96, 99.76)	1.00(-1.92, 6.08)	NA	0.6030
4-Fold Increase (%)	99.00(96.43, 99.88)	95.00(88.72, 98.36)	4.00(0.37, 10.27)	NA	0.0433
D28					
GMT	242.4(216.4, 271.4)	64.3(53.6, 77.2)	3.8(3.1, 4.6)	NA	< 0.0001
GMI	54.6(48.4, 61.6)	14.3(11.9, 17.1)	3.8(3.1, 4.7)	NA	< 0.0001
Seroconversion <sup>**</sup> (%)	99.50(97.25, 99.99)	98.00(92.96, 99.76)	1.50(-1.08, 6.55)	NA	0.2585
4-Fold Increase (%)	99.00(96.43, 99.88)	94.00(87.40, 97.77)	5.00(1.11, 11.57)	NA	0.0183
Delta					
Pre-Booster					
GMT	4.2(4.0, 4.4)	4.1(4.0, 4.3)	NA	<i>t</i> =0.532	0.5951

# 428 Table S2. Neutralizing antibodies to the wild-type SARS-CoV-2 as well as Delta and Omicron variants before and after booster.

	Seropositive <sup>*</sup> (%)	3.00(1.11, 6.42)	3.00(0.62, 8.52)	NA	NA	1.0000
D1	4					
	GMT	286.8(252.9, 325.3)	56.5(45.6, 70.0)	5.1(4.0, 6.4)	NA	< 0.0001
	GMI	68.5(60.1, 78.0)	13.7(11.1, 17.0)	5.0(3.9, 6.3)	NA	< 0.0001
	Seroconversion	99.00(96.43, 99.88)	96.00(90.07, 98.90)	3.00(-0.38, 8.93)	NA	0.0979
	4-Fold Increase (%)	99.00(96.43, 99.88)	91.00(83.60, 95.80)	8.00(3.35, 15.32)	NA	0.0011
D2	8					
	GMT	257.8(225.7, 294.5)	39.8(32.1, 49.3)	6.5(5.1, 8.2)	NA	< 0.0001
	GMI	61.5(53.7, 70.5)	9.7(7.8, 11.9)	6.4(5.0, 8.1)	NA	< 0.0001
	Seroconversion <sup>*</sup> (%)	99.00(96.43, 99.88)	95.00(88.72, 98.36)	4.00(0.37, 10.27)	NA	0.0433
	4-Fold Increase (%)	99.00(96.43, 99.88)	81.00(71.93, 88.16)	18.00(11.27, 26.87)	NA	< 0.0001
Omicr	on (For Subgroup)	N=80	N=40			
D2	8					
	GMT	28.1(21.4, 36.8)	6.4(5.0, 8.3)	4.4(2.9, 6.7)	NA	< 0.0001
	Seropositive <sup>*</sup> (%)	83.75(73.82, 91.05)	35.00(20.63, 51.68)	48.75(30.82, 63.84)	NA	< 0.0001

429 The geometric mean of titer (GMT) and geometric mean of increase against the pre-booster level (GMI) are presented with corresponding 2-sided 95%

430 confidence interval (CI) respectively in AWcorna and CoronaVac groups, and the ratios of GMT or GMI between the two groups and corresponding 95% CI
 431 are accordingly showed.

432 The non-inferiority result would be concluded if the lower bound of 95% CI of the ratio between groups (AWcorna/CoronaVac) is larger than 2/3 When the

433 non-inferiority conclusion is concluded, the superiority would be considered sequentially if the lower bound was larger than 1.

The seroconversion rate and the 4-fold Increase rate with their corresponding Clopper-Pearson 95% CI are shown, and the difference between the two groups
 were calculated using Miettinen-Nurminen method.

436 N=the number of participants included the per-protocol population. The p values are the results of comparison between the AWcorna and CoronaVac groups.
437

438 \*Seropositive defined as the status that the nAb level of a subject achieved the threshold of 1:8 (Limit of Detection, LOD).

439 \*\*Seroconversion due to booster dose at a subject level is defined as a change from below the LOD to equal or above LOD, or for those who above the LOD

440 pre-booster experienced at least a 4-fold rise in terms of nAbs.

#### 442 Table S3. RBD-Specific antibodies before and after booster.

	AWcorna	CoronaVac	GMT/GMI Ratio (AWcorna /CoronaVac)	Statistics	P value
	N=200	N=100	or Diff. in % (AWcorna -CoronaVac)		
Pre-Booster					
GMT	134.7(118.3, 153.4)	140.8(115.3, 172.0)	NA	<i>t</i> =-0.378	0.7061
Seropositive*(%)	100.00(98.17, 100.00)	100.00(96.38, 100.00)	NA	NA	1.0000
D14					
GMT	29270.4(26074.5, 32858.1)	4317.8(3680.1, 5065.9)	6.8 (5.6, 8.3)	NA	< 0.0001
GMI	217.3(184.9, 255.3)	30.7(25.5, 36.9)	7.1 (5.5, 9.2)	NA	< 0.0001
Seroconversion <sup>*</sup> (%)	99.50(97.25, 99.99)	98.00(92.96, 99.76)	1.50(-1.08, 6.55)	NA	0.2585
4-Fold Increase(%)	99.50(97.25, 99.99)	98.00(92.96, 99.76)	1.50(-1.08, 6.55)	NA	0.2585
D28					
GMT	21874.4(19568.4, 24452.3)	3102.3(2661.8, 3615.8)	7.1 (5.8, 8.5)	NA	< 0.0001
GMI	162.4(138.0, 191.1)	22.0(18.4, 26.4)	7.4 (5.7, 9.6)	NA	< 0.0001
Seroconversion*(%)	99.00(96.43, 99.88)	95.00(88.72, 98.36)	4.00(0.37, 10.27)	NA	0.0433
4-Fold Increase(%)	99.00(96.43, 99.88)	95.00(88.72, 98.36)	4.00(0.37, 10.27)	NA	0.0433

443 The geometric mean of titer (GMT) and geometric mean of increase against the pre-booster level (GMI) are presented with corresponding 2-sided 95%

444 confidence interval (CI) respectively in AWcorna and CoronaVac groups, and the ratios of GMT or GMI between the two groups and corresponding 95% CI

445 are accordingly showed.

- The seroconversion rate and the 4-fold Increase rate with their corresponding Clopper-Pearson 95% CI are shown, and the difference between the two groups
   were calculated using Miettinen-Nurminen method.
- 448 N=the number of subjects included the per-protocol population. The p values are the results of comparison between the AWcorna and CoronaVac groups.
- \*Seropositive defined as the status that the nAb level of a subject achieved the threshold of 1:10 (Limit of Detection, LOD).
- 450 \*\* Seroconversion due to booster dose at a subject level is defined as a change from below the LOD to equal or above LOD, or for those who above the LOD
- 451 pre-booster experienced at least a 4-fold rise in terms of nAbs.

Event Name	AWcorna (N=200)	CoronaVac (N=100)	<i>P</i> -Value
Severity	n(%)	n(%)	
AE (Any)	139(69.5)	20(20)	<0.0001
Grade1	85(42.5)	12(12)	<0.0001
Grade2	71(35.5)	6(6)	<0.0001
Grade3	22(11)	3(3)	0.0246
Grade4	0(0)	0(0)	1
Grade5	0(0)	0(0)	1
≥Grade2	84(42)	9(9)	<0.0001
≥Grade3	22(11)	3(3)	0.0246
Solicited AE (Any)	138(69)	20(20)	<0.0001
Grade1	85(42.5)	12(12)	<0.0001
Grade2	69(34.5)	6(6)	<0.0001
Grade3	22(11)	3(3)	0.0246
Grade4	0(0)	0(0)	1
≥Grade2	83(41.5)	9(9)	<0.0001
≥Grade3	22(11)	3(3)	0.0246
Systemic (Any)	131(65.5)	20(20)	<0.0001
Grade1	73(36.5)	12(12)	<0.0001
Grade2	67(33.5)	6(6)	<0.0001
Grade3	20(10)	3(3)	0.0372
Grade4	0(0)	0(0)	1
≥Grade2	82(41)	9(9)	<0.0001
≥Grade3	20(10)	3(3)	0.0372
Fever (FDA Standard, Any)	67(33.5)	4(4)	<0.0001
Grade1	39(19.5)	2(2)	<0.0001
Grade2	20(10)	2(2)	0.0100
Grade3	8(4)	0(0)	0.0555
Grade4	0(0)	0(0)	1
≥Grade2	28(14)	2(2)	0.0008
≥Grade3	8(4)	0(0)	0.0555

Table S4. Solicited and unsolicited adverse reactions that occurred within 28 days after booster
 vaccination.

Diarrhea (Any)	0(0)	0(0)	1
Grade1	0(0)	0(0)	1
Grade2	0(0)	0(0)	1
Grade3	0(0)	0(0)	1
Grade4	0(0)	0(0)	1
≥Grade2	0(0)	0(0)	1
≥Grade3	0(0)	0(0)	1
Nausea (Any)	5(2.5)	1(1)	0.6674
Grade1	4(2)	0(0)	0.3052
Grade2	1(0.5)	0(0)	1
Grade3	0(0)	1(1)	0.3333
Grade4	0(0)	0(0)	1
≥Grade2	1(0.5)	1(1)	1
≥Grade3	0(0)	1(1)	0.3333
Vomiting (Any)	5(2.5)	1(1)	0.6674
Grade1	5(2.5)	0(0)	0.1734
Grade2	0(0)	0(0)	1
Grade3	0(0)	1(1)	0.3333
Grade4	0(0)	0(0)	1
≥Grade2	0(0)	1(1)	0.3333
≥Grade3	0(0)	1(1)	0.3333
Headache (Any)	52(26)	7(7)	<0.0001
Grade1	11(5.5)	3(3)	0.3993
Grade2	41(20.5)	3(3)	<0.0001
Grade3	0(0)	1(1)	0.3333
Grade4	0(0)	0(0)	1
≥Grade2	41(20.5)	4(4)	< 0.0001
≥Grade3	0(0)	1(1)	0.3333
Muscle Aches (Any)	15(7.5)	1(1)	0.0255
Grade1	5(2.5)	0(0)	0.1734
Grade2	9(4.5)	1(1)	0.1732
Grade3	1(0.5)	0(0)	1
Grade4	0(0)	0(0)	1

≥Grade2	10(5)	1(1)	0.1073
≥Grade3	1(0.5)	0(0)	1
Joint Pain (Any)	6(3)	1(1)	0.4310
Grade1	3(1.5)	0(0)	0.5533
Grade2	2(1)	1(1)	1
Grade3	1(0.5)	0(0)	1
Grade4	0(0)	0(0)	1
≥Grade2	3(1.5)	1(1)	1
≥Grade3	1(0.5)	0(0)	1
Chills (Any)	10(5)	1(1)	0.1073
Grade1	7(3.5)	1(1)	0.2765
Grade2	3(1.5)	0(0)	0.5533
Grade3	0(0)	0(0)	1
Grade4	0(0)	0(0)	1
≥Grade2	3(1.5)	0(0)	0.5533
≥Grade3	0(0)	0(0)	1
Fatigue (Any)	4(2)	0(0)	0.3052
Grade1	2(1)	0(0)	0.5541
Grade2	1(0.5)	0(0)	1
Grade3	1(0.5)	0(0)	1
Grade4	0(0)	0(0)	1
≥Grade2	2(1)	0(0)	0.5541
≥Grade3	1(0.5)	0(0)	1
Rash (Not at Injection Site, Any)	0(0)	1(1)	0.3333
Grade1	0(0)	0(0)	1
Grade2	0(0)	0(0)	1
Grade3	0(0)	1(1)	0.3333
Grade4	0(0)	0(0)	1
≥Grade2	0(0)	1(1)	0.3333
≥Grade3	0(0)	1(1)	0.3333
Hypersensitivity (Any)	1(0.5)	0(0)	1
Grade1	0(0)	0(0)	1
Grade2	1(0.5)	0(0)	1

Grade3	0(0)	0(0)	1
Grade4	0(0)	0(0)	1
≥Grade2	1(0.5)	0(0)	1
≥Grade3	0(0)	0(0)	1
Local AE (Any)	34(17)	2(2)	<0.0001
Grade1	26(13)	2(2)	0.0013
Grade2	7(3.5)	0(0)	0.0998
Grade3	2(1)	0(0)	0.5541
Grade4	0(0)	0(0)	1
≥Grade2	9(4.5)	0(0)	0.0319
≥Grade3	2(1)	0(0)	0.5541
Pain at Injection Site (Any)	34(17)	2(2)	<0.0001
Grade1	25(12.5)	2(2)	0.0021
Grade2	7(3.5)	0(0)	0.0998
Grade3	2(1)	0(0)	0.5541
Grade4	0(0)	0(0)	1
≥Grade2	9(4.5)	0(0)	0.0319
≥Grade3	2(1)	0(0)	0.5541
Induration (Any)	0(0)	0(0)	1
Grade1	0(0)	0(0)	1
Grade2	0(0)	0(0)	1
Grade3	0(0)	0(0)	1
Grade4	0(0)	0(0)	1
≥Grade2	0(0)	0(0)	1
≥Grade3	0(0)	0(0)	1
Redness (Any)	0(0)	0(0)	1
Grade1	0(0)	0(0)	1
Grade2	0(0)	0(0)	1
Grade3	0(0)	0(0)	1
Grade4	0(0)	0(0)	1
≥Grade2	0(0)	0(0)	1
≥Grade3	0(0)	0(0)	1
Rash (at Injection Site, Any)	0(0)	0(0)	1

Grade1	0(0)	0(0)	1
Grade2	0(0)	0(0)	1
Grade3	0(0)	0(0)	1
Grade4	0(0)	0(0)	1
≥Grade2	0(0)	0(0)	1
≥Grade3	0(0)	0(0)	1
Swelling (Any)	2(1)	0(0)	0.5541
Grade1	2(1)	0(0)	0.5541
Grade2	0(0)	0(0)	1
Grade3	0(0)	0(0)	1
Grade4	0(0)	0(0)	1
≥Grade2	0(0)	0(0)	1
≥Grade3	0(0)	0(0)	1
Itch (Any)	0(0)	0(0)	1
Grade1	0(0)	0(0)	1
Grade2	0(0)	0(0)	1
Grade3	0(0)	0(0)	1
Grade4	0(0)	0(0)	1
≥Grade2	0(0)	0(0)	1
≥Grade3	0(0)	0(0)	1
Unsolicited AE (Any)	2(1)	1(1)	1
Grade1	0(0)	0(0)	1
Grade2	2(1)	0(0)	0.5541
Grade3	0(0)	1(1)	0.3333
Grade4	0(0)	0(0)	1
Grade5	0(0)	0(0)	1
≥Grade2	2(1)	1(1)	1
≥Grade3	0(0)	1(1)	0.3333

454 Data are n (%). n, number of participants; %, percentage of participants; any, all participants with any grade

455 of adverse reactions. The analysis was based on the per-protocol population. P values shown in bold are 456 <0.05.